SequelSEC

Natera, Inc. NTRA

Services-Medical Laboratories · CIK 0001604821 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$2.71B
Fiscal year ended 2026-06-30
Operating income
-$289.67M
Fiscal year ended 2026-06-30
Free cash flow
$84.20M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$21.83BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$154.02Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue9.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity12.7×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Services-Medical Laboratories filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth35.9%80th
SBC / revenue15.4%80th
FCF margin4.7%65th
R&D / revenue27.1%62th
CapEx / revenue4.6%53th
Net margin-9.0%52th
Operating margin-13.4%52th
Current ratio3.39x52th

Natera, Inc. (NTRA) reported revenue of $2.71B and net income of -$192.35M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Natera, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Medical Laboratories.

Income

Natera, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$2.71B
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$289.67M
Net income-$192.35M
Research & development$787.38M
Weighted-average diluted sharesUnavailable
Pretax income-$252.70M
Income tax expense-$60.36M
Diluted EPSUnavailable
Selling, general & administrative$1.25B
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Natera, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalentsUnavailable
Total assets$2.66B
Current assets$1.66B
Total liabilities$836.00M
Current liabilities$553.20M
Total equity incl. NCI$1.82B
Temporary (mezzanine) equityUnavailable
Inventory$80.35M
Accounts receivable$421.97M
Goodwill$141.10M
Long-term debtUnavailable
Accounts payable$75.15M

Cash flow

Natera, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$228.24M
Capital expenditures$144.04M
Investing cash flow-$187.06M
Financing cash flow$50.30M
Net change in cashUnavailable
Stock-based compensation$381.42M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$52.67M

Derived

Natera, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$84.20M
Gross marginUnavailable
Operating margin-10.7%
FCF margin3.1%
SBC / revenue14.1%
Current ratio3.00x
Revenue YoY growth37.8%
Net margin-7.1%
R&D / revenue29.1%
CapEx / revenue5.3%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NTRA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-02-27View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

ACON ADVB AMS BDSX BGLC BLLN CAI CDNA CELC CFOR CSTL DGX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.